Revascularisation ‐ PCI · patients with coronary heart disease
Exercise‐based cardiac rehabilitation showed no clear difference in revascularisation ‐ PCI compared with 'no exercise' control (moderate certainty).
1 finding from 1 review
Hospital admissions · patients with coronary heart disease
Exercise‐based cardiac rehabilitation probably leads to lower all‐cause hospital admissions compared with 'no exercise' control (moderate certainty).
1 finding from 1 review
Cardiovascular hospital admissions · patients with coronary heart disease
Exercise‐based cardiac rehabilitation showed no clear difference in cardiovascular hospital admissions compared with 'no exercise' control (low certainty).
1 finding from 1 review
All‐cause death · patients with heart failure with sinus rhythm
Warfarin showed no clear difference in all‐cause death compared with placebo or no treatment (low certainty).
1 finding from 1 review
Stroke · patients with heart failure with sinus rhythm
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Major bleeding · patients with heart failure with sinus rhythm
Warfarin may leads to higher major bleeding eventsc compared with placebo or no treatment (low certainty).
1 finding from 1 review
All‐cause death · patients with heart failure with sinus rhythm
Rivaroxaban showed no clear difference in all‐cause death compared with placebo (high certainty).
1 finding from 1 review
Stroke · patients with heart failure with sinus rhythm
Rivaroxaban probably leads to lower stroke compared with placebo (moderate certainty).
1 finding from 1 review
Major bleeding · patients with heart failure with sinus rhythm
Rivaroxaban probably leads to higher major bleeding eventsb compared with placebo (moderate certainty).
1 finding from 1 review
All‐cause mortality maximum · patients with coronary heart disease
Antibiotics showed no clear difference in all‐cause mortality at maximum compared with placebo or no intervention (high certainty).
1 finding from 1 review
Quality of life at 24±6 months · patients with coronary heart disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cardiovascular mortality · patients with coronary heart disease
Antibiotics leads to higher cardiovascular mortality at 24±6 months compared with placebo or no intervention (high certainty).
2 findings from 1 review
Myocardial infarction · patients with coronary heart disease
Antibiotics showed no clear difference in myocardial infarction at 24±6 months compared with placebo or no intervention (moderate certainty).
2 findings from 1 review
Stroke · patients with coronary heart disease
Antibiotics showed no clear difference in stroke at 24±6 months compared with placebo or no intervention (high certainty).
2 findings from 1 review
Sudden cardiac death · patients with coronary heart disease
Antibiotics probably leads to higher sudden cardiac death at 24±6 months compared with placebo or no intervention (moderate certainty).
2 findings from 1 review
Serious adverse events maximum · patients with coronary heart disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life at maximum · patients with coronary heart disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at 24±6 months · patients with coronary heart disease
Antibiotics leads to higher all‐cause mortality at 24±6 months compared with placebo or no intervention (high certainty).
1 finding from 1 review
Serious adverse event at 24±6 months · patients with coronary heart disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Depression symptoms ‐ short‐term · health problem or population
1 finding from 1 review